The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. [revisión]
Por: Ciruelos Gil, Eva María [Oncología Médica] | Pascual Martínez, Pascual [Oncología Médica] | Arroyo Vozmediano, María Luisa [Obstetricia y Ginecología] | Blanco Guerrero, Marta [Obstetricia y Ginecología] | Manso Sánchez, Luis [Oncología Médica] | Parrilla Rubio, Lucía [Oncología Médica] | Muñoz, César [Oncología Médica] | Vega Alonso, Estela [Oncología Médica] | Calderón, Monica Jackelin [Oncología Médica] | Sancho, Blanca [Obstetricia y Ginecología] | Cortés-Funes Castro, Hernán [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica | Servicio de Obstetricia y Ginecología.
Tipo de material: ArtículoEditor: The Breast : official journal of the European Society of Mastology, 2014Descripción: 23(3):201-8.Recursos en línea: Solicitar documento Resumen: Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant. Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy. The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs. Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile. In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
Revisión | PC16649 (Navegar estantería) | Disponible |
Navegando Hospital Universitario 12 de Octubre Estantes Cerrar el navegador de estanterías
Formato Vancouver:
Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014 Jun;23(3):201-8.
PMID: 24589524
Contiene 51 referencias
Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant. Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy. The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs. Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile. In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.
No hay comentarios para este ejemplar.